A meritorious integrated medical regimen for hepatic fibrosis and its complications via the systematic review and meta-analysis for Dahuang Zhechong pill-based therapy
BackgroundHepatic fibrosis is a health challenge due to the absence of satisfactory therapy, especially at the cirrhosis stage. Dahuang Zhechong pill (DHZCP)-based therapy is reportedly a successful treatment for hepatic fibrosis and is even beneficial for the treatment of cirrhosis. Hence, a system...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.920062/full |
| _version_ | 1811338986706173952 |
|---|---|
| author | Zhen Ye Qinfeng Huang Yingqi She Yu Hu Mingquan Wu Kaihua Qin Linzhen Li Chuantao Zhang Xiaohong Zuo Ailing Wei Dewen Mao Qiaobo Ye |
| author_facet | Zhen Ye Qinfeng Huang Yingqi She Yu Hu Mingquan Wu Kaihua Qin Linzhen Li Chuantao Zhang Xiaohong Zuo Ailing Wei Dewen Mao Qiaobo Ye |
| author_sort | Zhen Ye |
| collection | DOAJ |
| description | BackgroundHepatic fibrosis is a health challenge due to the absence of satisfactory therapy, especially at the cirrhosis stage. Dahuang Zhechong pill (DHZCP)-based therapy is reportedly a successful treatment for hepatic fibrosis and is even beneficial for the treatment of cirrhosis. Hence, a systematic review and clinical evidence assessment of DHZCP-based therapy should be performed, and clinical recommendations based on its efficacy for the treatment of hepatic fibrosis should be generated. With respect to potential indicators, the comparative value of the hepatic function, spleen thickness, and portal vein internal diameter should be evaluated.Materials and methodsPubMed, the Excerpta Medica Database, the Cochrane Library, the Web of Science, the WanFang Database, the Chinese Scientific Journal Database, and the Chinese National Knowledge Infrastructure database were searched to identify clinical trials. Three subgroup analyses were performed based on the stage of disease, medication use, and the course of treatment. Statistical analyses were performed using Review Manager 5.4.ResultsA total of 18 studies including 1,494 patients were evaluated. The DHZCP-based therapy was effective in reducing the plasma levels of hyaluronic acid, and laminin, procollagen III, and IV collagen were also reduced irrespective of the hepatitis stage or the presence of hepatic cirrhosis. Abnormalities in alanine aminotransferase, aspartate aminotransferase, albumin, and total bilirubin were reversed. A 6-month course of treatment was the most beneficial DHZCP-based therapy regimen. Alanine aminotransferase improvement was more obvious in patients with cirrhosis, and alanine aminotransferase was reduced significantly in patients with hepatic cirrhosis. With respect to pharmacological mechanisms, DHZCP-based therapy could inhibit hepatic stellate cell growth and activation, reduce inflammation, and prevent extracellular matrix formation. Hepatic portal hypertension and splenomegaly were ameliorated significantly in the DHZCP-based therapy group.ConclusionDahuang Zhechong pill-based therapy has demonstrated efficacy as a treatment for hepatic fibrosis and cirrhosis. A 6-month course of treatment is the recommended option for DHZCP-based therapy in clinical practice. The combination of DHZCP-based therapy and entecavir is a favorable treatment for hepatic cirrhosis. |
| first_indexed | 2024-04-13T18:18:31Z |
| format | Article |
| id | doaj.art-249fd19bde6b4dc8a5749d1e3c8eab64 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-13T18:18:31Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-249fd19bde6b4dc8a5749d1e3c8eab642022-12-22T02:35:32ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-10-01910.3389/fmed.2022.920062920062A meritorious integrated medical regimen for hepatic fibrosis and its complications via the systematic review and meta-analysis for Dahuang Zhechong pill-based therapyZhen Ye0Qinfeng Huang1Yingqi She2Yu Hu3Mingquan Wu4Kaihua Qin5Linzhen Li6Chuantao Zhang7Xiaohong Zuo8Ailing Wei9Dewen Mao10Qiaobo Ye11School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaDepartment of Oncology, The First Affiliated Hospital, Guangxi University of Chinese Medicine, Nanning, ChinaSchool of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaSchool of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaDepartment of Pharmacy, Sichuan Orthopedic Hospital, Chengdu, Sichuan, ChinaHealth Preservation and Rehabilitation College, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, ChinaSchool of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaDepartment of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, ChinaSchool of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaDepartment of Liver Disease, The First Affiliated Hospital, Guangxi University of Chinese Medicine, Nanning, ChinaDepartment of Liver Disease, The First Affiliated Hospital, Guangxi University of Chinese Medicine, Nanning, ChinaSchool of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaBackgroundHepatic fibrosis is a health challenge due to the absence of satisfactory therapy, especially at the cirrhosis stage. Dahuang Zhechong pill (DHZCP)-based therapy is reportedly a successful treatment for hepatic fibrosis and is even beneficial for the treatment of cirrhosis. Hence, a systematic review and clinical evidence assessment of DHZCP-based therapy should be performed, and clinical recommendations based on its efficacy for the treatment of hepatic fibrosis should be generated. With respect to potential indicators, the comparative value of the hepatic function, spleen thickness, and portal vein internal diameter should be evaluated.Materials and methodsPubMed, the Excerpta Medica Database, the Cochrane Library, the Web of Science, the WanFang Database, the Chinese Scientific Journal Database, and the Chinese National Knowledge Infrastructure database were searched to identify clinical trials. Three subgroup analyses were performed based on the stage of disease, medication use, and the course of treatment. Statistical analyses were performed using Review Manager 5.4.ResultsA total of 18 studies including 1,494 patients were evaluated. The DHZCP-based therapy was effective in reducing the plasma levels of hyaluronic acid, and laminin, procollagen III, and IV collagen were also reduced irrespective of the hepatitis stage or the presence of hepatic cirrhosis. Abnormalities in alanine aminotransferase, aspartate aminotransferase, albumin, and total bilirubin were reversed. A 6-month course of treatment was the most beneficial DHZCP-based therapy regimen. Alanine aminotransferase improvement was more obvious in patients with cirrhosis, and alanine aminotransferase was reduced significantly in patients with hepatic cirrhosis. With respect to pharmacological mechanisms, DHZCP-based therapy could inhibit hepatic stellate cell growth and activation, reduce inflammation, and prevent extracellular matrix formation. Hepatic portal hypertension and splenomegaly were ameliorated significantly in the DHZCP-based therapy group.ConclusionDahuang Zhechong pill-based therapy has demonstrated efficacy as a treatment for hepatic fibrosis and cirrhosis. A 6-month course of treatment is the recommended option for DHZCP-based therapy in clinical practice. The combination of DHZCP-based therapy and entecavir is a favorable treatment for hepatic cirrhosis.https://www.frontiersin.org/articles/10.3389/fmed.2022.920062/fullDahuang Zhechong pillhepatic fibrosistherapysystematic reviewmeta-analysis |
| spellingShingle | Zhen Ye Qinfeng Huang Yingqi She Yu Hu Mingquan Wu Kaihua Qin Linzhen Li Chuantao Zhang Xiaohong Zuo Ailing Wei Dewen Mao Qiaobo Ye A meritorious integrated medical regimen for hepatic fibrosis and its complications via the systematic review and meta-analysis for Dahuang Zhechong pill-based therapy Frontiers in Medicine Dahuang Zhechong pill hepatic fibrosis therapy systematic review meta-analysis |
| title | A meritorious integrated medical regimen for hepatic fibrosis and its complications via the systematic review and meta-analysis for Dahuang Zhechong pill-based therapy |
| title_full | A meritorious integrated medical regimen for hepatic fibrosis and its complications via the systematic review and meta-analysis for Dahuang Zhechong pill-based therapy |
| title_fullStr | A meritorious integrated medical regimen for hepatic fibrosis and its complications via the systematic review and meta-analysis for Dahuang Zhechong pill-based therapy |
| title_full_unstemmed | A meritorious integrated medical regimen for hepatic fibrosis and its complications via the systematic review and meta-analysis for Dahuang Zhechong pill-based therapy |
| title_short | A meritorious integrated medical regimen for hepatic fibrosis and its complications via the systematic review and meta-analysis for Dahuang Zhechong pill-based therapy |
| title_sort | meritorious integrated medical regimen for hepatic fibrosis and its complications via the systematic review and meta analysis for dahuang zhechong pill based therapy |
| topic | Dahuang Zhechong pill hepatic fibrosis therapy systematic review meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.920062/full |
| work_keys_str_mv | AT zhenye ameritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT qinfenghuang ameritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT yingqishe ameritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT yuhu ameritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT mingquanwu ameritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT kaihuaqin ameritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT linzhenli ameritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT chuantaozhang ameritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT xiaohongzuo ameritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT ailingwei ameritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT dewenmao ameritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT qiaoboye ameritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT zhenye meritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT qinfenghuang meritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT yingqishe meritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT yuhu meritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT mingquanwu meritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT kaihuaqin meritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT linzhenli meritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT chuantaozhang meritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT xiaohongzuo meritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT ailingwei meritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT dewenmao meritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy AT qiaoboye meritoriousintegratedmedicalregimenforhepaticfibrosisanditscomplicationsviathesystematicreviewandmetaanalysisfordahuangzhechongpillbasedtherapy |